Overexpression of c‑Met increases the tumor invasion of human prostate LNCaP cancer cells in vitro and in vivo

Han,Yili; Luo,Yong; Zhao,Jiahui; Li,Mingchuan; Jiang,Yongguang

doi:10.3892/ol.2014.2390

Overexpression of c‑Met increases the tumor invasion of human prostate LNCaP cancer cells in vitro and in vivo

Authors:
- Yili Han
- Yong Luo
- Jiahui Zhao
- Mingchuan Li
- Yongguang Jiang
View Affiliations

Affiliations: Department of Urology, Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing 100029, P.R. China
Published online on: July 28, 2014 https://doi.org/10.3892/ol.2014.2390
Pages: 1618-1624

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

c‑Met is a transmembrane tyrosine kinase receptor that may be activated by hepatocyte growth factor, an inducer of epithelial‑mesenchymal transition (EMT), to regulate the associated downstream gene expression. This process is critical to cell migration in normal and pathological conditions. In the present study, the function of c‑Met in the process of EMT was investigated in prostate cancer. Initially, a c‑Met stable expression cell line was constructed using EMT‑ and c‑Met‑negative LNCaP prostate cancer cells. Following the identification of c‑Met in the transfected cells, the changes in EMT, phosphatidylinositol 3‑kinase (PI3K) and extracellular signal‑regulated kinase pathway biomarkers were determined by western blot analysis. MTT, soft agar and Transwell assays, and xenograft studies were used to investigate the effects of c‑Met on the proliferation, migration and tumorigenicity of LNCaP cells. The results of the present study revealed downregulation of E‑cadherin and upregulation of vimentin in LNCaP‑Met cells. The results demonstrated that c‑Met enhanced proliferation, migration and tumorigenicity capacity when compared with LNCaP and LNCaP‑pcDNA3.1 cells. Furthermore, these EMT‑like changes were mediated via the PI3K and mitogen‑activated protein kinase signaling pathways. The present study clearly demonstrates a crucial function for c‑Met in EMT development in prostate cancer. c‑Met‑targeted treatment may be an effective adjuvant therapy for improving survival rates in patients with prostate cancer.

View Figures

View References

1	Jeffers M, Rong S and Vande Woude GF: Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signaling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol. 16:1115–1125. 1996.
2	Ponzetto C, Bardelli A, Zhen Z, et al: A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell. 77:261–271. 1994.
3	Birchmeier C and Gherardi E: Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol. 8:404–410. 1998.
4	Bhardwaj V, Cascone T, Cortez MA, et al: Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy. Cancer. 119:1768–1775. 2013.
5	Gibney GT, Aziz SA, Camp RL, et al: c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol. 24:343–349. 2013.
6	Knudsen BS and Vande Woude G: Showering c-Met dependent cancers with drugs. Curr Opin Genet Dev. 18:87–96. 2008.
7	De Bacco F, Luraghi P, Medico E, et al: Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst. 103:645–661. 2011.
8	Qian LW, Mizumoto K, Inadome N, et al: Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells. Int J Cancer. 104:542–549. 2003.
9	Graveel CR, Tolbert D and Vande Woude GF: MET: a critical player in tumorigenesis and therapeutic target. Cold Spring Harb Perspect Biol. 5:a0092092013.
10	Luraghi P, Schelter F, Krüger A and Boccacciol C: The MET oncogene as a therapeutical target in cancer invasive growth. Front Pharmacol. 3:1642012.
11	Feng Y, Thiagarajan PS and Ma PC: MET signaling: novel targeted inhibition and its clinical development in lung cancer. J Thorac Oncol. 7:459–467. 2012.
12	Li B, Torossian A, Sun Y, Du R, Dicker AP and Lu B: Higher levels of c-Met expression and phosphorylation identify cell lines with increased sensitivity to AMG-458, a novel selective c-Met inhibitor with radiosensitizing effects. Int J Radiat Oncol Biol Phys. 84:e525–e531. 2012.
13	Seiden-Long I, Navab R, Shih W, et al: Gab1 but not Grb2 mediates tumor progression in Met overexpressing colorectal cancer cells. Carcinogenesis. 29:647–655. 2008.
14	Chung JY, Davis JA, Price BD, et al: Competitive enhancement of HGF-induced epithelial scattering by accessory growth factors. Exp Cell Res. 317:307–318. 2011.
15	Ogunwobi OO and Liu C: Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathway. Clin Exp Metastasis. 28:721–731. 2011.
16	Previdi S, Maroni P, Matteucci E, Broggini M, Bendinelli P and Desiderio MA: Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and β-catenin/Wnt pathways. Eur J Cancer. 46:1679–1691. 2010.
17	Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenbach AC and Chung LW: c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol. 154:293–298. 1995.
18	Cecchi F, Rabe DC and Bottaro DP: Targeting the HGF/Met signaling pathway in cancer. Eur J Cancer. 46:1260–1270. 2010.
19	Luo Y, He DL and Ning L: Expression of ‘epithelial-mesenchymal transition’ associated proteins in prostate cancer cell lines with different metastatic potentials and its significance. Zhonghua Nan Ke Xue. 12:696–700. 2006.(In Chinese).
20	McKeithen D, Graham T, Chung LW and Odero-Marah V: Snail transcription factor regulates neuroendocrine differentiation in LNCaP prostate cancer cells. Prostate. 70:982–992. 2010.
21	Wang Y, Yue D, Li K, Liu YL, Ren CS and Wang P: The role of TRPC6 in HGF-induced cell proliferation of human prostate cancer DU145 and PC3 cells. Asian J Androl. 12:841–852. 2010.
22	Tate A, Isotani S, Bradley MJ, Sikes RA, Davis R, Chung LW and Edlund M: Met-independent hepatocyte growth factor-mediated regulation of cell adhesion in human prostate cancer cells. BMC Cancer. 6:1972006.
23	Książkiewicz M, Markiewicz A and Zaczek AJ: Epithelial-mesenchymal transition: a hallmark in metastasis formation linking circulating tumor cells and cancer stem cells. Pathobiology. 79:195–208. 2012.
24	Voutsadakis IA: The ubiquitin-proteasome system and signal transduction pathways regulating Epithelial Mesenchymal transition of cancer. J Biomed Sci. 19:672012.
25	Matsuoka J, Yashiro M, Doi Y, et al: Hypoxia stimulates the EMT of gastric cancer cells through autocrine TGFβ signaling. PLoS One. 8:e623102013.
26	Luo Y, He DL, Ning L, et al: Over-expression of hypoxia-inducible factor-1α increases the invasive potency of LNCaP cells in vitro. BJU Int. 98:1315–1319. 2006.
27	Lamouille S, Subramanyam D, Blelloch R and Derynck R: Regulation of epithelial-mesenchymal and mesenchymal-epithelial transitions by microRNAs. Curr Opin Cell Biol. 25:200–207. 2013.
28	Davidson B, Tropé B and Reich R: Epithelial-mesenchymal transition in ovarian carcinoma. Front Oncol. 2:332012.
29	Hamada S, Satoh K, Masamune A and Shimosegawa T: Regulators of epithelial mesenchymal transition in pancreatic cancer. Front Physiol. 3:2542012.
30	Talbot LJ, Bhattacharya SD and Kuo PC: Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies. Int J Biochem Mol Biol. 3:117–136. 2012.
31	Leopold PL, Vincent J and Wang H: A comparison of epithelial-to-mesenchymal transition and re-epithelialization. Semin Cancer Biol. 22:471–483. 2012.
32	Navab R, Liu J, Seiden-Long I, et al: Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells. Neoplasia. 11:1292–1300. 2009.
33	Garnett J, Chumbalkar V, Vaillant B, et al: Regulation of HGF expression by ΔEGFR-mediated c-Met activation in glioblastoma cells. Neoplasia. 15:73–84. 2013.
34	Varkaris A, Gaur S, Parikh NU, et al: Ligand-independent activation of MET through IGF-1/IGF-1R signaling. Int J Cancer. 133:1536–1546. 2013.
35	Nurwidya F, Takahashi F, Murakami A and Takahashi K: Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res Treat. 44:151–156. 2012.
36	Shimada S, Mimata A, Sekine M, et al: Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer. Gut. 61:344–353. 2012.
37	Jahn SC, Law ME, Corsino PE, et al: An in vivo model of epithelial to mesenchymal transition reveals a mitogenic switch. Cancer Lett. 326:183–190. 2012.
38	Martin TA, Mason MD and Jiang WG: Hepatocyte growth factor signaling in cancer metastasis. Curr Signal Transduct Ther. 6:180–190. 2011.
39	Thiery JP, Acloque H, Huang RY and Nieto A: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009.
40	Gentile A, Trusolino L and Comoglio PM: The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev. 27:85–94. 2008.
41	Birchmeier C, Birchmeier W, Gherardi E and Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 4:915–925. 2003.
42	Benvenuti S and Comoglio PM: The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol. 213:316–325. 2007.
43	Torres KE, Zhu QS, Bill K, et al: Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res. 17:3943–3955. 2011.
44	Lengyel E, Prechtel D, Resau JH, et al: C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer. 113:678–682. 2005.
45	Zhou AX, Toylu A, Nallapalli RK, et al: Filamin a mediates HGF/c-MET signaling in tumor cell migration. Int J Cancer. 128:839–846. 2011.
46	Inagaki Y, Qi F, Gao J, et al: Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth. Biosci Trends. 5:52–56. 2011.
47	Falchook GS, Fu S, Amin HM, et al: Phase I dose-escalation study of the oral selective C-Met inhibitor EMD 1204831 in patients with advanced solid tumours. Eur J Cancer. 47:S1582011.
48	Yap TA, Olmos D, Brunetto AT, et al: Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol. 29:1271–1279. 2011.